[Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine]
- PMID: 16172951
- DOI: 10.1055/s-2005-916351
[Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine]
Abstract
Background and objective: Allogeneic transplantation can not be offered to many patients due to potential side-effects of conventional conditioning. Dose-reduced conditioning approaches improve tolerability, however, treatment efficacy may be reduced as well. We have, therefore, developed a dose intense but toxicity reduced conditioning regimen based on treosulfan and fludarabine and report first results.
Patients and methods: 65 patients with a median age of 50 years were transplanted from related (n = 21) or unrelated donors (n = 44) after conditioning with treosulfan (3 x 10, 3 x 12 or 3 x 14 g/m(2) i. v.) and fludarabine (5 x 30 mg/m(2) i. v.). 21 patients were in complete remission (CR) and 44 patients had not reached a CR at the time of transplantation. 59 of 65 patients were considered unfit for a conventional conditioning regimen.
Results: The actuarial overall survival after 3 years is 59.2 %, the event-free survival 40.1 %. Patients with a related donor or transplantation in CR had a better overall (85.4 resp. 74.2 %) and event-free survival (52.2 % resp. 61.9 %). The cumulative incidence of relapse at 3 years was 26.2 %. Non-relapse mortality at day 100 is 17.4 % (cumulative incidence). In stepwise Cox regression analyses for overall survival, event-free survival and non-relapse mortality the covariables transplantation in CR vs. not in CR and the donor status were shown to be influential.
Conclusions: These results with a conditioning therapy of treosulfan and fludarabine indicate that patients despite higher age, concomitant disease or after intensive pretreatment can be successfully transplanted without increased treatment-related mortality.
Similar articles
-
Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.Br J Haematol. 2008 Jun;142(2):284-92. doi: 10.1111/j.1365-2141.2008.07179.x. Epub 2008 May 19. Br J Haematol. 2008. PMID: 18492101 Clinical Trial.
-
Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.J Clin Oncol. 2010 Jul 10;28(20):3344-51. doi: 10.1200/JCO.2009.23.3429. Epub 2010 May 24. J Clin Oncol. 2010. PMID: 20498405
-
A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.Bone Marrow Transplant. 2001 Oct;28(7):643-7. doi: 10.1038/sj.bmt.1703215. Bone Marrow Transplant. 2001. PMID: 11704786
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.Bone Marrow Transplant. 2008 Oct;42 Suppl 2:S67-70. doi: 10.1038/bmt.2008.287. Bone Marrow Transplant. 2008. PMID: 18978748 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources